Akums Reports 26% Profit Fall Amid Tax Probe; Proposes ₹3 Dividend

Akums Drugs & Pharmaceuticals announced a 26% decline in its FY26 profit after tax, which fell to ₹256.40 crore from ₹343.78 crore in the prior year. The company's board has recommended a total dividend of ₹3 per share, pending shareholder approval, while an ongoing Income Tax investigation initiated in FY25 continues to cast an unascertainable financial risk.

Profit Dip and Dividend Payout

The fiscal year ended March 31, 2026, saw Akums post ₹256.40 crore in consolidated profit after tax, a decrease of ₹87.38 crore compared to FY25's ₹343.78 crore. The Board of Directors has proposed a ₹1.00 final dividend and a ₹2.00 special dividend for FY26, contingent upon shareholder approval at the upcoming Annual General Meeting. In terms of operational continuity, the company confirmed the re-appointment of M/s. Balwinder & Associates as cost auditors and appointed Mahajan & Aibara LLP as internal auditors for FY 2026-27. Senior management also saw a change, with Mr. V Jagannathan appointed as President - HR.

Tax Probe Uncertainty Lingers

The significant drop in profit comes as Akums faces an ongoing Income Tax investigation. This probe stems from search and seizure operations conducted in January 2024 (FY25), which led to the issuance of show cause notices to the company. The exact financial impact of these proceedings remains undetermined, presenting a material risk that could affect future earnings and operational stability. Potential consequences could include penalties, additional tax liabilities, or operational disruptions, adding a layer of uncertainty for all stakeholders.

Company Background and Funding

Akums Drugs & Pharmaceuticals operates primarily in India's contract research and manufacturing services (CRAMS) sector, focusing on formulating medicines for other companies. This business model allows it to utilize its manufacturing expertise without direct brand marketing. The company completed its Initial Public Offering (IPO) in December 2022, raising approximately ₹650 crore. These funds were designated for capital expenditure, working capital enhancement, and general corporate purposes. As of FY2026, only ₹4.81 crore of the ₹642.18 crore net IPO proceeds remained unutilized.

Industry Peers

Akums competes in the pharmaceutical CRAMS space alongside companies such as Laurus Labs, Syngene International, and Divi's Laboratories. While Akums specializes in formulation manufacturing for others, its peers often offer a broader range of services, including API production and comprehensive contract research. These competitors also navigate complex regulatory landscapes but may possess different financial strengths and risk profiles.

Investor Outlook

Shareholders await approval for the proposed ₹3 per share dividend. The key factors to monitor will be the resolution of the Income Tax Department's proceedings and any clarity on their financial implications. Updates on the utilization of remaining IPO funds and any management commentary on strategies to navigate profit pressures and regulatory challenges will also be crucial for investors.